starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.
Company profile
Ticker
ITOS
Exchange
Website
CEO
Michel Detheux
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
iTeos Therapeutics S.A. • iTeos Securities Corporation • iTeos BE, LLC ...
ITOS stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Regulation FD Disclosure
10 Jan 24
8-K
Departure of Directors or Certain Officers
7 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Departure of Directors or Certain Officers
26 Jun 23
8-K
Departure of Directors or Certain Officers
20 Jun 23
EFFECT
Notice of effectiveness
22 May 23
424B3
Prospectus supplement
19 May 23
Latest ownership filings
4
Matthew Gall
8 Mar 24
4
Matthew Call
8 Mar 24
4
Yvonne McGrath
8 Mar 24
4
Michel Detheux
8 Mar 24
4
Jill DeSimone
7 Mar 24
3
Jill DeSimone
7 Mar 24
SC 13G
EcoR1 Capital, LLC
16 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 204.40 mm | 204.40 mm | 204.40 mm | 204.40 mm | 204.40 mm | 204.40 mm |
Cash burn (monthly) | 4.03 mm | 45.67 mm | 14.43 mm | 7.34 mm | 11.30 mm | 9.76 mm |
Cash used (since last report) | 27.36 mm | 310.28 mm | 98.01 mm | 49.87 mm | 76.75 mm | 66.33 mm |
Cash remaining | 177.04 mm | -105.88 mm | 106.39 mm | 154.53 mm | 127.66 mm | 138.07 mm |
Runway (months of cash) | 44.0 | -2.3 | 7.4 | 21.1 | 11.3 | 14.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 15 |
Closed positions | 16 |
Increased positions | 58 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 384.29 bn |
Total shares | 39.14 mm |
Total puts | 215.30 k |
Total calls | 286.46 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 5.05 mm | $55.31 bn |
Ra Capital Management | 4.42 mm | $48.37 bn |
MPM Asset Management | 2.74 mm | $29.99 bn |
MPM BioVentures 2014 | 1.84 mm | $59.33 mm |
Vanguard | 1.81 mm | $19.86 bn |
Biotechnology Value Fund L P | 1.81 mm | $0.00 |
Boxer Capital | 1.80 mm | $19.75 bn |
MPM Oncology Impact Management | 1.75 mm | $19.12 bn |
STT State Street | 1.58 mm | $17.32 bn |
BVF | 1.26 mm | $13.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Jill DeSimone | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 44,766 | 518.39 k | 44,766 |
7 Mar 24 | Yvonne McGrath | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 153,600 | 1.78 mm | 153,600 |
7 Mar 24 | Michel Detheux | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 590,400 | 6.84 mm | 590,400 |
7 Mar 24 | Matthew Gall | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 163,200 | 1.89 mm | 163,200 |
News
JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $27
12 Mar 24
HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $44 Price Target
7 Mar 24
Recap: ITeos Therapeutics Q4 Earnings
6 Mar 24
ITeos Therapeutics Q4 EPS $(0.85) Beats $(1.03) Estimate, Cash and Investment Position Of $632.7M Is Expected To Provide Cash Runway Through 2026
6 Mar 24
iTeos To Highlight Preclinical Data On First-In-Class EOS-984 Targeting ENT1 At The American Association For Cancer Research Annual Meeting 2024
5 Mar 24
Press releases
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
7 Apr 24
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
6 Mar 24
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
5 Mar 24
iTeos to Participate in Upcoming Investor Conferences
1 Mar 24